SCHEMBL2393258

SCHEMBL2393258

CCOC(=O)C(F)(Br)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 1/20 0.51
POLB P06746 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
MMP8 P22894 1/20 0.49
MAPT P10636 4/20 0.48
THRB P10828 2/20 0.48
ALDH1A1 P00352 2/20 0.46
RECQL P46063 1/20 0.45
CHRM2 P08172 1/20 0.45
CHRM4 P08173 1/20 0.45
CHRM5 P08912 1/20 0.45
CHRM1 P11229 1/20 0.45
CHRM3 P20309 1/20 0.45
HDAC4 P56524 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
HDAC3 O15379 1/20 0.45
HDAC1 Q13547 1/20 0.45
TSHR P16473 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4526778 0.86 PIN1 (0.51) PIN1POLBNPSR1MMP8MAPT
SCHEMBL27854388 0.84 PIN1 (0.50) PIN1POLBNPSR1MMP8MAPT
SCHEMBL5010275 0.84 PIN1 (0.53) PIN1POLBNPSR1MMP8MAPT
SCHEMBL9725190 0.84 PIN1 (0.53) PIN1POLBNPSR1MMP8MAPT
SCHEMBL1172441 0.84 PIN1 (0.53) PIN1POLBNPSR1MMP8MAPT
SCHEMBL27502753 0.83 POLB (0.52) PIN1POLBNPSR1MMP8MAPT
SCHEMBL5816392 0.82 POLB (0.55) PIN1POLBNPSR1MMP8MAPT
SCHEMBL2422372 0.81 PIN1 (0.54) PIN1POLBNPSR1MMP8MAPT
SCHEMBL29156932 0.81 CHRM2 (0.64) PIN1POLBNPSR1MMP8ALDH1A1
SCHEMBL2910521 0.81 PIN1 (0.54) PIN1POLBNPSR1MMP8MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PIN1 3532/4885POLB 4657/4885NPSR1 2461/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PIN1 3532/4885POLB 4657/4885NPSR1 2461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.